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Abstract: Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with 
moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β2 ago-
nist bronchodilators. This review considers the mechanism of action, pharmacokinetics, efficacy, safety and place in management of 
omalizumab in asthma and focuses particularly on key articles published over the last three years. Omalizumab reduces IgE mediated 
airway inflammation and its effect on airway remodeling is under investigation. Recent long-term clinical trials confirm the benefits of 
omalizumab in reducing exacerbations and symptoms in adults and in children with moderate to severe allergic asthma. No clinical or 
immunological factor consistently predicts a good therapeutic response to omalizumab in allergic asthma. In responders, the duration 
of treatment is unclear. The main adverse effect of omalizumab is anaphylaxis, although this occurs infrequently. Preliminary data from 
a five-year safety study has raised concerns about increased cardiovascular events and a final report is awaited. Clinical trials are in 
progress to determine whether omalizumab has efficacy in the treatment of non-allergic asthma.
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Introduction
Over 300 million individuals worldwide have asthma1 
of whom the majority have mild or moderate disease 
that can be controlled by inhaled corticosteroids, 
either alone or in combination with inhaled long-
acting β2 agonist bronchodilators.1–3 Nevertheless 
a considerable proportion of patients with asthma,4 
particularly those with severe disease5 have poorly 
controlled symptoms and are at increased risk 
of exacerbations. In some patients inadequately 
controlled asthma is due to poor adherence with 
treatment, untreated co-morbidities, dysfunctional 
breathing or psychological problems.6,7 For others, 
there is a need for additional or new therapies.8 
Severe asthma occurs in 5% to 10% of the asthmatic 
population and in this group it is estimated that 
over 50% have allergic IgE-mediated asthma.9 
Omalizumab, a recombinant humanized monoclonal 
antibody that binds circulating IgE antibody, is a 
treatment option for moderate to severe allergic 
asthma in patients whose asthma is not well controlled 
with inhaled corticosteroids and inhaled long-acting 
β2 agonist bronchodilators.1–3 This review considers 
the mechanism of action, pharmacokinetics, efficacy, 
safety and place in management of omalizumab 
in asthma and focuses particularly on key articles 
published over the last three years.
Mechanism of Action
Immunoglobulin E (IgE) is considered to play a key 
role in the pathogenesis of asthma10 and the level 
of circulating IgE to common inhalant allergens is 
a strong risk factor for emergency admissions with 
asthma.11 Allergen specific IgE binds to high affinity 
receptors (F
CεRI) on mast cells and basophils to induce 
an allergic reaction through the release of a wide 
range of inflammatory mediators such as histamine, 
tryptase and arachidonic acid metabolites.12,13 High 
affinity receptors are also expressed on other inflam-
matory cells including dendritic cells, monocytes and 
eosinophils. Omalizumab is a recombinant human-
ized monoclonal antibody that binds to the F
C
  portion 
of the IgE antibody. By forming complexes with 
circulating IgE antibody it reduces the levels of free 
IgE and prevents the binding of IgE to high-affinity 
IgE receptors on mast cells and basophils and the sub-
sequent release of inflammatory mediators induced 
by allergen exposure14 (Fig. 1). Omalizumab cannot 
however, bind to IgE that has already attached to 
F
CεRI receptors. Omalizumab treatment also down-
regulates the expression of F
CεRI receptors on mast 
cells and basophils.15
There is considerable interest in determining 
the effects of omalizumab treatment on chronic 
airway inflammation and remodeling in asthma.16–19 
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Figure 1. Mechanisms of action of omalizumab in allergic asthma.
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Immunol,14 copyright 2008.
Abbreviation: Fc RI, high-affinity IgE receptor.
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A placebo controlled study of 16 weeks treatment 
with omalizumab in forty-five patients with mild to 
moderate persistent asthma with sputum eosinophilia 
of 2% or more found that active treatment resulted 
in a reduction of bronchial biopsy IgE+ cells in 
the airway mucosa, tissue eosinophil numbers 
and CD3+, CD4+, and CD8+ T lymphocytes.16 
Omalizumab treatment was not associated however, 
with improvement in airway hyperresponsiveness to 
methacholine. In addition to reducing the early and 
late bronchoconstrictor response to inhaled allergen, 
omalizumab reduces induced sputum eosinophils and 
bronchial biopsy eosinophil numbers and IgE-bearing 
cells, but does not attenuate airway responsiveness 
to methacholine post-allergen challenge.17 A pooled 
analysis of data from five randomized controlled 
studies in 2236 patients with moderate to severe 
persistent allergic asthma receiving moderate to 
high-dose inhaled corticosteroids found a pattern 
of improved clinical outcomes, associated with 
decreased peripheral blood eosinophils and worse 
clinical outcomes associated with increased 
peripheral blood eosinophils, in keeping with the 
efficacy of omalizumab being due, at least in part, 
with an inhibitory effect on eosinophils.20 Treatment 
of allergic subjects with omalizumab also reduces 
the release of Th2 cytokines from peripheral blood 
basophils.13 Taken together these studies suggest that 
treatment with omalizumab reduces eosinophilic 
airway inflammation and IgE-bearing cells, but does 
alter airway responsiveness. Possible mechanisms 
for the reduction in eosinophil numbers, although 
not established,21 could be explained by a reduction 
in high affinity IgE receptor numbers on dendritic 
cells causing less antigen presentation to T cells, by 
decreased release of eosinophilic chemotactic factors 
from mast cells and basophils and by the induction 
of eosinophil apoptosis.22 In addition, omalizumab 
blocks low affinity IgE receptors on epithelial cells 
and airway smooth muscle, which may decrease the 
release of eosinophil chemokines such as eotaxin.21
There is limited information on the effects of 
omalizumab on airway remodeling.19 Prevention 
of degranulation of allergen bound mast cells by 
omalizumab prevents the release of pro-inflammatory 
cytokines, including IL-4, IL-13 and IL-5 that are 
associated with airway remodeling. The exhaled 
breath condensate levels of endothelin-1, a pro-
inflammatory mediator also implicated in asthmatic 
airway inflammation and remodeling23 are reduced 
following omalizumab, suggesting a potential 
mechanism by which this therapy could reduce 
structural changes to the airways.24 A 16 week study 
of 30 patients with severe persistent asthma, which 
used computed tomography (CT) to assess airway 
dimensions, found that treatment with omalizumab 
compared to usual care was associated with a 
reduction in indices of airway wall thickness.18 
Interestingly, the decrease in airway wall thickness 
was associated with improvements in lung function 
and decrease in sputum eosinophil count. A long-
term randomized controlled trial is underway in 
patients with moderate to severe allergic asthma 
to examine the effects of 78 weeks treatment with 
omalizumab on bronchial biopsy sub-epithelial 
eosinophils, mast cell and CD4+ T-lymphocytes 
as well as thickness of the lamina reticularis, as an 
index of airway remodeling (The EXPLORE study, 
www.clinicaltrials.gov NCT00670930). The findings 
of this study should provide insights into the effects 
of long-term treatment with omalizumab on airway 
inflammation and remodeling.
In summary, omalizumab decreases allergic 
airway inflammation by reducing the expression of 
high affinity IgE receptors on inflammatory cells and 
eosinophil numbers within the airways. Research is 
underway to help establish whether long-term treatment 
with omalizumab also reduces airway remodeling.
Metabolism and pharmacokinetic 
Profile
The metabolism and pharmacokinetic profile of 
omalizumab has been previously reviewed in detail.25 
After a single subcutaneous dose in adult and 
adolescents with asthma, omalizumab is absorbed 
slowly over several days, reaching peak serum 
concentrations after an average of seven to eight 
days.25,26 The pharmacokinetics of omalizumab are 
linear at doses above 0.5 mg per kg. Measurements 
of omalizumab serum concentrations reflect the 
combination of free omalizumab and that bound 
to IgE. Serum free IgE levels reduce in a dose-
dependent manner within one hour of the first 
dose of omalizumab and levels are maintained 
between doses, whereas concentrations of total IgE 
(ie, the sum of free and omalizumab bound IgE) 
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are increased. Information about drug distribution is 
limited to reports from intravenous administration of 
radiolabeled omalizumab in cynomolgus monkeys.27 
These studies suggest that most of the drug remains 
in the central intravascular compartment, with little 
accumulation in tissues. Elimination of omalizumab 
appears to involve IgG clearance processes as well as 
clearance via specific binding and complex formation 
with its target ligand, IgE. Liver elimination of IgG 
includes degradation in the reticulo-endothelial system 
and endothelial cells. Intact IgG is also excreted in 
bile. In patients with asthma, the omalizumab serum 
elimination half-life averages 26 days, with apparent 
clearance rates averaging 2.4 ± 1.1 mL per kg per day. 
In addition, doubling of body weight approximately 
doubles clearance rates. The half-life of omalizumab 
is variable, with values ranging from one to 
four weeks.25 After discontinuation of omalizumab, 
free and total IgE concentrations approach baseline 
slowly. In a dose-ranging study involving patients 
with ragweed seasonal allergic rhinitis, average free 
IgE concentrations returned to baseline within eight 
weeks of the last omalizumab infusion.28 Total IgE 
concentrations generally take longer to approach 
baseline after stopping therapy.28,29 One year after 
discontinuation of omalizumab dosing, circulating 
IgE levels return to baseline pre-treatment levels 
with no observed rebound.26 Analyses of population 
pharmacokinetics of omazulamab suggest that no 
dose adjustments are necessary for the age range 6 to 
76 years, race, ethnicity, gender or Body Mass Index. 
There are no pharmacokinetic or pharmacodynamic 
data in patients with renal or hepatic impairment.26
Efficacy
The main evidence for the efficacy of omalizumab 
in the treatment of patients with allergic asthma is 
summarized in two systematic reviews.30,31 A Cochrane 
review published in 2006 of 14 randomized con-
trolled trials in 3143 children and adults with mild 
to severe allergic asthma found that treatment with 
omalizumab reduced asthma exacerbations (OR 0.52, 
95% CI, 0.41 to 0.65) and increased the proportion of 
patients who were able to reduce or withdraw inhaled 
corticosteroids.30 A systematic review published in 2011 
of 8 randomized controlled trials in 3,429 children and 
adults with moderate to severe allergic asthma taking 
inhaled corticosteroids, including two trials published 
after 2006,32,33 concluded that omalizumab treatment 
resulted in a higher proportion of subjects stepping-
down and stopping inhaled corticosteroids (relative 
risk [RR] = 1.80; 95% CI, 1.42–2.28) and reduced 
the risk of asthma exacerbations (RR = 0.57; 95% CI, 
0.48–0.66).31 Data from the systematic review pub-
lished in 201131 suggested that the number needed to 
treat for benefit (NTTB) in reducing the rate of exacer-
bations was 10. A post-hoc analysis suggested that the 
beneficial effects of omalizumab were not dependent 
on the age, duration of treatment, or disease severity.31 
A study included in the systematic review that pro-
vided evidence for the efficacy of omalizumab in chil-
dren was a 52 week randomized placebo-controlled 
trial in 627 children aged 6 to ,12 years with peren-
nial allergen asthma and a history of exacerbations 
and poor symptom treatment with  medium-dose or 
high-dose inhaled corticosteroids with or without 
other controller medications.32 Omalizumab treatment 
reduced asthma exacerbations by 31% compared to 
placebo during the first 24-weeks of the study, when 
the inhaled corticosteroid dose remained stable, and 
by 43% over a period of 52 weeks, which included 
a 28-week adjustable-corticosteroid phase.32 In this 
study the secondary outcomes including symptoms, 
reliever bronchodilator use and reduction in inhaled 
corticosteroid dose were not significantly improved 
by omalizumab treatment.
Recent publications have provided important new 
information on the use of omalizumab as an add-on 
treatment to high dose inhaled corticosteroids and 
inhaled long-acting β2 agonist bronchodilators in 
severe allergic asthma34,35 and in children and young 
adults with allergic asthma36 (Table 1). A randomized 
controlled trial in 850 patients who had inadequately 
controlled asthma despite treatment with high dose 
inhaled corticosteroids ($500 mcg of fluticasone 
inhaler twice daily or equivalent) and inhaled long-
acting β2 agonist bronchodilators, with or without 
other controllers assessed the benefits of the addition of 
omalizumab over a 48 week period.34 At the end of the 
treatment period omalizumab produced a 25% relative 
reduction in the rate of asthma exacerbations (0.66 
omalizumab vs. 0.88 placebo per patient) (Table 1). 
This study demonstrates clinical benefits obtained from 
the addition of omalizumab to patients with poorly 
controlled severe allergic asthma despite treatment 
with high dose inhaled corticosteroids and inhaled 
Omalizumab in the management of asthma
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long-acting β2 agonist bronchodilators, although the 
magnitude of benefit is relatively small. Interestingly 
there was a large placebo effect observed in the control 
group, a finding which has been noted in previous 
studies with omalizumab.30,35 At baseline, seventeen 
percent of participants were receiving either chronic 
oral corticosteroids or an oral corticosteroid course at 
least 4 times per year, and in this sub-group there was 
no clinical benefit although it should be noted that the 
study was not powered to detect a treatment effect.
A recent double-blind, placebo-controlled 
study in 271 patients aged 12 years or older with 
physician diagnosed persistent allergic asthma com-
pared the efficacy of omalizumab with placebo over 
24 weeks period.35 There was no significant differ-
ence with omalizumab treatment in the change from 
baseline in the primary outcome measure, the Asthma 
Control Test (ACT) total score, compared with 
placebo. In a subgroup of patients with very poorly 
controlled asthma (ACT # 15) at baseline however, 
significant benefits were observed for omalizumab 
compared with placebo for change in ACT score. The 
results of this study suggest that omalizumab has little 
impact on ACT scores, except in those patients with 
very poorly controlled asthma.35
A randomized controlled trial in 419 inner-city 
children, adolescents, and young adults with persistent 
allergic asthma examined the benefits of the addition 
Table 1. Summary of recent key randomized placebo-controlled clinical trials of omalizumab as an add-on treatment in 
children and young adults with allergic asthma.
Author participants Duration Main outcomes
Hanania et al, 
Ann Int Med34
850 patients aged 12 to 75 years who 
had inadequately controlled asthma  
despite treatment with high dose  
inhaled corticosteroids ($500 mcg  
of fluticasone inhaler twice daily or  
equivalent) and inhaled long-acting  
β2 agonist bronchodilators, with or  
without other controllers
48 weeks At the end of the treatment period omalizumab 
produced a 25% relative reduction in the primary 
outcome, rate of asthma exacerbations  
(0.66 omalizumab vs. 0.88 placebo per patient, 
P = 0.006), as well as producing improvements  
in several secondary efficacy end-points including 
an non-clinically significant increase in the mean 
asthma quality of life questionnaire (AQLQ) 
score (0.29 points) and a decrease in mean daily 
number of puffs of albuterol (-0.27 puffs per day) 
and in mean total asthma symptom score  
(-0.26) compared with placebo.
Bardelas et al,  
J Asthma35
271 patients aged 12 years or older  
with physician diagnosed persistent 
allergic asthma
24 weeks There was no significant difference with 
omalizumab treatment in the change from 
baseline in the primary outcome, the Asthma 
Control Test (ACT) total score, compared  
with placebo. 
In a subgroup of patients with very poorly 
controlled asthma (ACT # 15) at baseline 
however, significant benefits were observed for 
omalizumab compared with placebo for change  
in ACT score.
Busse et al,  
N eng J Med36
419 inner-city children,  
adolescents, and young adults with  
persistent allergic asthma.  
Almost three quarters of participants  
had moderate or severe asthma
60 weeks At the end of the treatment period omalizumab, 
compared to placebo, produced a 25% relative 
reduction in the primary outcome, number 
of days with asthma symptoms, from 1.96 to 
1.48 days per 2 week interval (P , 0.001) as 
well as producing a reduction in the proportion 
of subjects who had one or more exacerbations 
from 48.8% in the placebo group to 30.3% in the 
omalizumab group and in the hospital admissions 
because of asthma from 6.3% to 1.5%.  
In addition, the omalizumab treatment group 
reduced the use of inhaled corticosteroids and 
inhaled long-acting β2 agonist bronchodilators.
Abbreviation: RCT, Randomized placebo controlled trial.
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of omalizumab to guideline based treatment over a 
60 week period.36 Almost three quarters of participants 
had moderate or severe asthma. At the end of the 
treatment period omalizumab, compared to placebo, 
produced a 25% relative reduction in the number of 
days with asthma symptoms (Table 1, Fig. 2) as well 
as producing a reduction in the proportion of subjects 
who had one or more exacerbations from 48.8% in 
the placebo group to 30.3% in the omalizumab group 
and in the hospital admissions because of asthma from 
6.3% to 1.5%. A post hoc analysis revealed a marked 
reduction in seasonal exacerbation with omalizumab. 
In addition to confirming the clinical benefits from 
omalizumab treatment in children and young adults 
with allergic asthma, this study provides evidence for 
the importance of sensitization to cockroach allergen 
and house dust mites in an inner-city US population 
of individuals with allergic asthma.
Several observational studies have reported on 
‘real life’ experience with omalizumab in treating 
patients with allergic asthma in France,37 Germany,38 
Belgium,39 United Kingdom,40 Italy,41 South-Eastern 
Mediterranean centers,42 Israel43 and Spain.44 The 
most recent and largest study reported on the efficacy, 
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Figure 2. Omalizumab in inner-city children, adolescents, and young adults with persistent allergic asthma. 
note: The figure shows the number of days with symptoms (per 2-week interval), frequency of exacerbations, and dose of inhaled glucocorticoid over the 
duration of the study. 
Reproduced from Busse et al with permission.36 Copyright (c) Massachusetts Medical Society.
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tolerability and IgE entry criteria of omalizumab 
treatment of 266 patients with uncontrolled severe 
asthma receiving high dose inhaled corticosteroid and 
inhaled long-acting β2 agonist bronchodilators.44 The 
main efficacy outcome of exacerbations, ACT score 
and global evaluation of treatment effectiveness all 
improved at 4 months and at 2 years including patients 
with “off label” IgE levels. Omalizumab treatment 
was stopped in a minority of patients because of a 
lack of efficacy. The study provides data from a 
 longer follow-up period (over 2 years) than previous 
observational studies. Taken together, the results of 
these studies suggest that omalizumab is an effective 
treatment for patients with poorly controlled allergic 
asthma and that efficacy outcomes in a ‘real life’ 
setting are similar to those reported in clinical trials.
Omalizumab reduces the severity of the acute 
bronchoconstrictor response to environmental 
exposure to cat allergen.45 A randomized controlled 
trial undertaken in 69 patients who gave a history of 
cat allergen–induced asthma examined the effects 
of 16 weeks treatment with omalizumab or placebo 
on controlled exposure to cat allergen.45 After cat 
allergen exposure the area under the curve for 
percentage decrease in FEV1 was 15.2% per hour 
for omalizumab-treated patients compared with 
27.3% per hour for patients who received placebo. 
Symptoms caused by exposure to cat allergens were 
also reduced by treatment with omalizumab. These 
findings suggest that omalizumab may have a role in 
the treatment of patients with cat allergen–induced 
asthma when avoidance measures and/or drug therapy 
are not effective in controlling the severity of acute 
asthma symptoms during environmental exposure to 
cat allergen. A large proportion of patients with severe 
allergic asthma also have chronic allergic rhinitis and 
in this group of patients, omalizumab treatment over 
a 26 week period improves both asthma and rhinitis 
quality of life questionnaire scores.46
There is interest in whether omalizumab may be of 
value in the treatment of other forms of asthma includ-
ing non-allergic asthma. A case report of a patient with 
severe persistent asthma, who had elevated total IgE 
levels and negative specific IgE and skin-prick test 
results, noted a good clinical response to an open trial 
of omalizumab treatment, which was followed by a 
deterioration after its withdrawal.47 Several random-
ized controlled clinical trials are underway to assess 
the clinical and immunological effects of omalizumab 
in severe non-atopic asthma. The primary outcomes in 
one study are lung function and exacerbations (www.
clinicaltrials.gov NCT01113437), and in another 
study the expression of FcεRI receptors on blood 
basophils and dendritic cells (www.clinicaltrials.
gov NCT01007149). Hopefully the results of these 
clinical trials will help clarify the role of omalizumab 
therapy in the treatment of non-atopic asthma. A study 
to evaluate the effect of omalizumab on improving 
the tolerability of specific allergen immunotherapy in 
248 patients with at least moderate persistent allergic 
asthma, with the aim of reducing systemic allergic 
reactions, reported that the number of participants with 
systemic allergic reactions to specific immunother-
apy was numerically lower after 26 weeks treatment 
with omalizumab (13.5%) compared to placebo 
(26.2%).48 A observational study of 18 patients with 
aspergillus-associated airway diseases recruited from 
11 centers in Spain reported on the clinical benefits 
of omalizumab treatment for a median follow-up of 
36 weeks.49 The treatment was discontinued in five 
patients due to a lack of efficacy and one because of a 
positive pregnancy test. In the remaining 12 patients 
there were improvements in symptoms, exacerbations 
and lung function. Based on these preliminary find-
ings in patients with aspergillus sensitization associ-
ated asthma, prospective placebo controlled trials are 
indicated.
In summary, recent long-term clinical trials confirm 
the benefits of omalizumab in reducing exacerbations 
and symptoms in adults and in children with moderate 
to severe allergic asthma.
Safety
There is increasing data on the safety of the short and 
long term use of omalizumab, as numbers of patients 
in clinical trials and clinical use has expanded. An 
analysis of over 7,500 patients recruited to clinical 
trials of omalizumab and of 57,300 patients included 
in post-marketing safety follow-up monitoring 
revealed a generally favorable safety profile.50 The 
major adverse effect associated with the use of 
omalizumab is anaphylaxis. In addition concerns have 
been raised about an increase in malignancy rates and 
cardiovascular and cerebrovascular events (Table 2).
The incidence of anaphylaxis reported in clinical 
trials is 0.14% in omalizumab treated patients and 
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0.07% in control patients in clinical trials and 0.2% 
with omalizumab treatment from post-marketing 
data.50 Nearly 60% of anaphylactic episodes devel-
oped in the first two hours after the administration of 
omalizumab; 39% occurred after the first dose, 19% 
following the second and 10% with the third dose 
and a previous history of anaphylaxis was reported 
in 24% of subjects.51 Recommendations of the US 
Omalizumab Joint Task Force guideline published 
in 2007 include informed consent, patient education 
about anaphylaxis symptoms, supply of an epineph-
rine auto-injector and a waiting period of two hours 
following the first 3 injections and 30 minutes for sub-
sequent injections.52 According to the European Med-
icines Agency (EMA) licence, medications for the 
treatment of anaphylactic reactions should be avail-
able in areas where omalizumab is administered and 
patients should be informed of the potential for such 
reactions and the need for prompt medical attention 
should reactions occur.53
The overall incidence of observed malignancy 
associated with omalizumab use is rare and 
comparable to that in the general population.26,51 
In clinical trials in adults and adolescents, there 
was a numerical imbalance in cancers arising in the 
omalizumab group (0.5%) compared with the control 
group (0.18%).26 A causal relationship was considered 
unlikely given the diversity in the type of cancers, the 
relatively short duration of exposure and the clinical 
features of the individual cases.26 There were no cases 
of malignancy with omalizumab in the clinical trials 
in children 6 to ,12 years of age; there was a single 
case of malignancy in the control group.26 In a recent 
pooled analysis from 67 clinical trials including 
11,459 patients of whom 7789 received omalizumab, 
25 malignancies [14 and 11 in omalizumab and 
placebo treated patients respectively] were identified. 
Incidence rates per 1,000 patient-years of observation 
time for omalizumab- and placebo-treated patients 
were 4.14 (95% CI, 2.26–6.94) and 4.45 (95% 
CI, 2.22–7.94), respectively. No association was 
observed between omalizumab treatment and risk 
of malignancy suggesting that a causal relationship 
between omalizumab therapy and malignancy is not 
likely.54
Recently concerns about the cardiovascular 
and cerebrovascular safety of omalizumab have 
been raised by the United States Food and Drug 
 Administration (FDA), based on preliminary data 
from a five year epidemiological study designed to 
evaluate the clinical effectiveness and long-term safety 
in patients with moderate to severe asthma (EXELS).55 
Detailed results from this study are expected later this 
year. The numerical imbalance of arterial thrombotic 
events (ATEs) observed in clinical trials and in the 
EXCELS cohort, included stroke, transient ischemic 
attack, myocardial infarction, unstable angina, and 
cardiovascular death (including death from unknown 
cause). The rate of ATE in patients in the controlled 
clinical trials was 6.29 for omalizumab treated patients 
and 3.42 for control patients. In a Cox proportional 
hazards model, omalizumab was not associated with 
ATE risk (hazard ratio 1.86; 95% confidence interval 
0.73–4.72). In the observational study, the rate of ATE 
was 5.59 for omalizumab treated patients and 3.71 for 
control patients. In a multivariate analysis controlling 
Table 2. Adverse effects of omalizumab.†
common [,1/10]
• Pyrexia*
• Abdominal pain upper*
• Headache*
•  Injection site reactions such as swelling, erythema, 
pain, pruritus
Uncommon [.1/1000 to ,1/100]
• Pharyngitis
• Syncope, paraesthesia, somnolence, dizziness
• Postural hypotension, flushing
• Allergic bronchospasm, coughing
• Dyspeptic signs and symptoms, diarrhoea, nausea
• Photosensitivity, urticaria, rash, pruritus
•  Influenza-like illness, swelling arms, weight increase, 
fatigue
Rare [$1/10,000 to ,1/1000]
• Parasitic infection
• Anaphylactic reaction, other serious allergic conditions
• Laryngoedema
• Angioedema
Frequency not known [cannot be estimated from 
available data]
• Idiopathic severe thrombocytopenia
•  Serum sickness, may include fever and 
lymphadenopathy
•  Allergic granulomatous vasculitis (ie, Churg-Strauss 
syndrome)
• Alopecia
• Arthralgia, myalgia, joint swelling
notes: †Adapted from Summary of Product Characteristics;26 *very 
common in children 6 to ,12 years of age [$1/10].
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for baseline cardiovascular risk factors, omalizumab 
was not associated with ATE risk (hazard ratio 1.11; 
95% confidence interval 0.70–1.76).26
An exploratory study in Brazil studied whether 
anti-IgE treatment of patient with allergic asthma and/
or rhinitis would increase the risk of infections with 
intestinal helminths.56 Following a course of anti-
helminthic treatment, all subjects received omalizumab 
or placebo for 52 weeks. Half the omalizumab treated 
subjects experienced at least one intestinal helminth 
infection compared with 41% of placebo subjects, 
suggesting a slight increase in the incidence of 
helminth infection, although the difference was non-
significant. The current drug summary of product 
characteristics advises caution in patients at high risk 
of helminth infection, in particular when travelling 
to areas where these infections are endemic, and if 
patients do not respond to recommended anti-helminth 
treatment, discontinuation of omalizumab should be 
considered.26
Adverse events do not appear to occur more 
frequently in older people. An observational study in 
a ‘real life’ population of 280 people reported adverse 
events in 35.5% of patients 50 years or older and, at 
a similar frequency, in 32.1% of younger patients.57 
Omalizumab is designated a Pregnancy Category 
B drug and animal studies have not demonstrated 
a risk to the foetus.51 The EXPECT registry, an 
observational registry following women who have 
received omalizumab during pregnancy or prior 
to conception will provide further information. 
In the 27 cases of pregnancy occurring in patients 
receiving omalizumab in clinical trials, no significant 
issues were observed in abortion rates or abnormal 
deliveries.51 The current opinion is that due to lack of 
adequate data, omalizumab should not be used during 
pregnancy unless clearly necessary and women should 
not breast feed during therapy.26
In summary, the main adverse effect of omalizumab 
is anaphylaxis, although this occurs infrequently. 
 Preliminary data from a five-year safety study has 
raised concerns about increased cardiovascular events 
and a final report is awaited.
Place in Therapy
In 2003, omalizumab was approved by the FDA for 
the treatment of adults and adolescents aged 12 years 
and above with moderate to severe persistent allergic 
asthma whose symptoms are poorly controlled with 
inhaled corticosteroids.58 A Black Boxed adverse 
effects warning issued in 2007 advising of the risk of 
the delayed development of anaphylaxis after admin-
istration of omalizumab and a further warning issued 
in 2009 notified of interim safety findings from the 
EXCELS study of a possible increase in the number 
of cardiovascular and cerebrovascular adverse events 
in treated patients. The European Medicines Agency 
(EMA) licensed omalizumab in 2005 for the treatment 
of severe allergic asthma in patients aged 12 years 
or older in whom symptoms are poorly controlled, 
including a history of multiple exacerbations, despite 
inhaled high dose corticosteroids and inhaled long-
acting β2 agonist bronchodilators and in whom the 
FEV1 , 80%. In 2009 the licence was extended to 
include children aged 6 to ,12 years as an add-on 
treatment for poorly controlled asthma in patients with 
severe persistent allergic asthma.59 In addition to the 
US and Europe, omalizumab is licensed for treating 
patients with moderate to severe allergic asthma in a 
large number of other countries worldwide including 
Australia, Canada and Brazil.
current Guidelines
The US National Asthma Education and Prevention 
Expert Panel Report 3 (EPR-3) guideline,3 the 
international Global Initiative for Asthma (GINA) 
guideline1 and the British guideline on the management 
of asthma2 have similar recommendations on the man-
agement of chronic asthma, with step-wise treatment 
aimed at controlling symptoms. Steps 4 to 6 of the 
EPR-3 guideline and Steps 4 and 5 of the GINA and 
British guidelines are the stage at which asthma is 
considered severe. Anti-IgE therapy is recommended 
by the EPR-3 guidelines at steps 5 and 63 and the 
GINA1 and British2 guidelines for patients at step 5.
Indications
For the purpose of using omalizumab the term allergic 
is defined as a positive skin test or in vitro reactivity 
to a perennial aeroallergen and in addition the serum 
total IgE levels should be in the range 30 to 700 IU/
mL in the US. In Europe the serum total IgE ranges 
are $30 to #1500 IU/mL in adults and children .12 
years and ,1300 IU/mL for children over 6 years. 
The dose (mg) of omalizumab and dose frequency is 
based on the serum total IgE level (IU/mL) and the 
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patient’s body weight (kg). Based on this calculation, 
omalizumab is given at a dose of 150 to 375 mg by 
subcutaneous injection every 2 or 4 weeks. The main 
contraindication is a past history of a severe hyper-
sensitivity reaction to omalizumab. There is limited 
data on the efficacy of omalizumab in active ciga-
rette smokers with allergic asthma, as this group is 
usually excluded from clinical trials of omalizumab, 
although it is likely that the efficacy will be similar to 
that reported in non-smokers with allergic asthma.60
Assessment of Therapeutic Response
Several studies have tried to identify clinical or 
immunological factors that predict a good therapeutic 
response to omalizumab.61–63 Based on a pooled analysis 
from seven randomized controlled omalizumab trials, 
Bousquet and colleagues62 concluded that treatment 
benefits were not related to baseline total IgE levels. 
However, in the INvestigatioN of Omalizumab 
in seVere Asthma TrEatment (INNOVATE) study 
undertaken in patients with severe allergic asthma 
and included in the pooled analysis, baseline total 
IgE was the only predictor of efficacy64 and levels 
of specific IgE for individual allergens were of no 
additional benefit in predicting a positive response.63 
In inner-city US children, adolescents, and young 
adults with persistent allergic asthma the presence 
of sensitization and exposure to cockroach allergen 
predicted a very good response to omalizumab.36 
It has been reported that patients receiving long-
term oral corticosteroids or frequent courses of oral 
corticosteroids respond poorly to omalizumab,34 
although there is some limited evidence to support an 
oral corticosteroid sparing effect of omalizumab.65 An 
open-label study of 82 patients with severe allergic 
asthma, found the addition of omalizumab therapy 
resulted in lower mean (SD) percent maintenance 
oral corticosteroid use after 32 weeks of treatment 
(-45.0%) compared with that in 23 patients who 
received usual care (18.3%).65
It is recommended that a decision is made whether 
to continue long-term treatment based on assessment 
of response made after 16 weeks of treatment,61 
although a recent study reported that the maximum 
effect of omalizumab occurred within 4 weeks of 
starting treatment.36 In several studies of omalizumab, 
the physician’s overall assessment at 16 weeks 
following a course of treatment was the best predictor 
of a continuing beneficial response.62,66 Nevertheless 
the combination of objective measurements of 
efficacy, such as ACQ, as well as the physicians’ 
and patients’ overall assessment are often used to 
assess response, although these tools have not been 
validated. Cardiopulmonary exercise testing has been 
advocated as an additional method to assess and 
confirm a clinical response to omalizumab in patients 
with severe asthma although to date the utility of 
exercise testing as not been investigated in a large 
number of patients.67
Duration of treatment
Once a patient is considered to respond to omali-
zumab, treatment is then continued often for several 
years. It remains uncertain when treatment can be dis-
continued or whether prolonged treatment is required. 
Certainly a dose reduction at 6 months, in patients 
who were responders at 16 weeks, is associated with 
a recurrence of symptoms.68 A small study of patients 
with severe cat allergen-induced asthma reported 
good symptom control and reduced basophil aller-
gen sensitivity three years following completion of 
six years treatment with omalizumab,69 suggesting 
that treatment may not need to be indefinite, although 
whether this conclusion applies to patients who do 
not have cat allergen-induced asthma is not known.
special populations
There is no clear indication on the safety of 
omalizumab in pregnancy, although animal studies in 
monkeys have not reported adverse effects. Physicians 
need to assess the risk and benefits of treatment with 
omalizumab during pregnancy on an individual basis. 
In the US, a pregnancy exposure register has been 
established to help provide observational data on 
the use of omalizumab. There is limited data in the 
efficacy and safety of omalizumab in older patients 
over 65 years. Since omalizumab prevents seasonal 
peaks in asthma exacerbations it has been suggested 
that a seasonal course of treatment in individuals at 
high risk should be studied, as this approach would 
reduce the cost of treatment.36 A recommendation 
for the use of omalizumab in the treatment of non-
allergic asthma and other sub-groups of asthma will be 
informed by the results of clinical trials underway.
In summary, omalizumab is a treatment option 
for patients with moderate to severe allergic asthma 
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whose asthma is poorly controlled with inhaled 
corticosteroids and inhaled long-acting β2 agonist 
bronchodilators. No clinical or immunological fac-
tors consistently predict a good therapeutic response 
to omalizumab in allergic asthma. In responders, the 
duration of treatment is unclear. Clinical trials are 
underway to determine whether omalizumab has effi-
cacy in the treatment of non-allergic asthma.
cost
An assessment of the cost effectiveness of omalizumab 
in adults and adolescents with  moderate-to-severe 
allergic asthma concluded that treatment should be 
reserved for patients with poorly controlled symp-
toms despite maximal therapy, given the high cost 
and modest efficacy of omalizumab.70 A cost effec-
tiveness analysis relevant to the US population sug-
gests that adding omalizumab to usual care improves 
quality-adjusted survival (QALYs), but at an increase 
in direct medical costs; the incremental cost-effec-
tiveness ratio (ICER) of omalizumab compared to 
usual care was $172 300/QALY in responders.71 
Similar conclusions were reported from a cost effec-
tiveness analysis based on a ‘real-life’ 1-year ran-
domized open-label study using costs in  Canada.72 
Uncertainty has been expressed over the excess mor-
tality rates applied to severe exacerbations used in 
models in the UK to assess the cost- effectiveness 
of omalizumab.73 Due to the high cost of treatment, 
individual countries have issued specific criteria for 
use of omalizumab to maximise benefit in selected 
populations of patients. For example, in the UK, the 
National Institute of Health and Clinical Excellence 
(NICE) recommends that omalizumab should only 
be used in adult patients who give a history of two 
or more severe exacerbations of asthma requiring 
admission to hospital within the previous year, or 
three or more severe exacerbations within the pre-
vious year including at least one of which required 
hospital admission.74 NICE does not recommended 
omalizumab for the treatment of severe persistent 
allergic asthma in children aged 6–11 years based 
on a review that concluded that omalizumab in addi-
tion to standard therapy compared with standard 
therapy alone did not appear cost-effective in either 
the overall population or a subgroup of patients hos-
pitalised in the year prior to enrolment.75 In Scotland, 
the Scottish Medicines Consortium (SMC) restricts 
its use to patients with chronic oral corticosteroid 
dependent severe allergic asthma.76
conclusions
Omalizumab is a recombinant humanized 
monoclonal antibody that binds circulating IgE 
antibody. It is approved in the US and Europe, as 
well as many other countries, for the treatment of 
adults and adolescents aged 12 years and above 
with moderate to severe persistent allergic asthma, 
whose symptoms are poorly controlled with inhaled 
corticosteroids, plus in Europe patients should 
also be receiving inhaled long-acting β2 agonist 
bronchodilators. In Europe, the licence also includes 
children aged 6 to ,12 years as an add-on treatment 
for poorly controlled asthma in patients with 
severe persistent allergic asthma. Both national and 
international guidelines recommend omalizumab 
for patients with severe allergic asthma that is 
not controlled with other therapies. Omalizumab 
decreases allergic airway inflammation by reducing 
the expression of high affinity IgE receptors on 
inflammatory cells and eosinophil numbers within 
the airways. Research is underway to help establish 
whether long-term treatment with omalizumab 
also reduces airway remodeling. Recent long-term 
clinical trials confirm the benefits of omalizumab in 
reducing exacerbations and symptoms in adults and 
in children with moderate to severe allergic asthma. 
No clinical or immunological factors consistently 
predict a good therapeutic response to omalizumab 
in allergic asthma. In responders, the duration of 
treatment is unclear. The main adverse effect of 
omalizumab is anaphylaxis, although this occurs 
infrequently. Preliminary data from a five year safety 
study raised concerns about increased cardiovascular 
events and a final report is awaited. Clinical trials 
are in progress to determine whether omalizumab 
has efficacy in the treatment of non-allergic asthma.
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